srf388
srf388: developed by 1 company · 1 clinical trial tracked.
srf388 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect srf388 to SURF; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could srf388 → SURF affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| Surface Oncology, Inc. (SURF) | Phase 1 |
Clinical Trials (1)
A Randomized Phase 2 Trial of Atezolizumab and Bevacizumab in Combination With SRF388 or Placebo in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Primary endpoint: Nature, frequency, and severity of adverse events (AEs) per NCI CTCAE version 5.0 or higher
InterventionalRandomizedquadruple30 enrolledStarted 2022-04Completion 2025-0737 sites · Australia, South Korea, Taiwan, United StatesCoherus Oncology, Inc.
Frequently asked questions
Who is developing srf388?
srf388 is being developed by Surface Oncology, Inc..
How many clinical trials involve srf388?
BioSniper tracks 1 clinical trial involving srf388.